Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats

Liver International

Volumn 33, Issue 2, 2013, Pages 301-311

  Okada, Yoshihisa ^a   Yamaguchi, Kanji ^a   Nakajima, Tomoki ^b   Nishikawa, Taichiroh ^a   Jo, Masayasu ^a   Mitsumoto, Yasuhide ^a   Kimura, Hiroyuki ^a   Nishimura, Takeshi ^a   Tochiki, Nozomi ^a   Yasui, Kohichiroh ^a   Mitsuyoshi, Hironori ^a   Minami, Masahito ^a   Kagawa, Keizo ^a   Okanoue, Takeshi ^c   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Saiseikai Kyoto Hospital   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

High fat and high cholesterol diets; NASH; Rosuvastatin

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ACYL COENZYME A OXIDASE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CARNITINE PALMITOYLTRANSFERASE I; CATALASE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FATTY ACID; INTERLEUKIN 6; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; ROSUVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS; HYPERCHOLESTEROLEMIA; LIPID DIET; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER INJURY; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; STEATOSIS;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ACYL-COA OXIDASE; ALANINE TRANSAMINASE; ANIMALS; AZO COMPOUNDS; CARNITINE O-PALMITOYLTRANSFERASE; CATALASE; CHOLESTEROL; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 84872161504     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12033     Document Type: Article

References (48)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clinic Proc 1980; 55: 434-8.
2. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
3. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
4. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
5. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6.
6. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
7. Lopez LM. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor. J Am Pharm Assoc (2003) 2005; 45: 503-13.
8. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 5: 499-508.
9. Kurisu S, Ishibashi K, Kato Y, et al. Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels 2011. [Epub ahead of print].
10. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 13: 1556-65.
11. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 21: 2195-207.
12. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009; 31: 127-42.
13. Sironi L, Gianazza E, Gelosa P, et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005; 25: 598-603.
14. Naito Y, Katada K, Takagi T, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 2006; 17: 997-1004.
15. Kim YS, Ahn Y, Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007; 49: 376-83.
16. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via up-regulation of glutathione synthesis. Atherosclerosis 2008; 199: 278-87.
17. Malaguarnera M, Vacante M, Russo C, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011; 11: 92-8.
18. Burke JP, Watson RW, Murphy M, et al. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg 2009; 96: 541-51.
19. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133: 1172-80.
20. Rodrigues-Díez R, Rodrigues-Díez R, Lavoz C, et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS ONE 2010; 5: e14145.
21. Koepke ML, Weber M, Schulze-Lohoff E, et al. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 2007; 22: 1062-9.
22. Gianella A, Nobili E, Abbate M, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007; 170: 1165-77.
23. Solini A, Rossi C, Santini E, et al. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation. J Hypertens 2011; 29: 1930-9.
24. Watts KL, Cottrell E, Hoban PR, Spiteri MA. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir Res 2006; 7: 88.
25. Yang JI, Yoon JH, Bang YJ, et al. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest 1Liver Physiol 2010; 298: G126-32.
26. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702-12.
27. Knas M, Stypulkowska A, Lukivskaya O, et al. Effects of statins on liver fibrosis reversibility and activities of lysosomal exoglycosidases. J Clin Exp Hepatol 2007; 3: 14-17.
28. Matsuzawa N, Takamura T, Kurita S, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-403.
29. Jeong WI, Jeong DH, Do SH, et al. Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 2005; 67: 235-242.
30. Savard C, Tartaglione EV, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2012. [Epub ahead of print].
31. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4: 9-14.
32. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.
33. Chan J, Sharkey FE, Kushwaha RS, Vandeberg JF, Vandeberg JL. Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. Am J Physiol Gastrointest Liver Physiol 2012; 303: G12-9.
34. Roglans N, Verd JC, Peris C, et al. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 2002; 37: 445-54.
35. Ekstedt M, Franzén LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-41.
36. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-71.
37. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-4.
38. Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012; 123: 259-70.
39. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci USA 2001; 98: 1477-82.
40. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665.
41. Arteel GE. Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH? Hepatology 2012; 55: 2030-2.
42. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-403.
43. Egawa T, Toda K, Nemoto Y, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 2003; 38: 519-23.
44. Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-62.
45. Choi HC, Song P, Xie Z, et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem 2008; 283: 20186-97.
46. Farrell GC, Van Rooyen DM. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol 2012; 303: G9-11.
47. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35(11 Suppl. 1): 2708-11.
48. Mayer C, Gruber HJ, Landl EM, et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007; 45: 319-27.